Does Anastrozole Cause High Blood Pressure?

Anastrozole can raise blood pressure, though the evidence is more mixed than you might expect from a straightforward yes-or-no question. In clinical studies, women taking aromatase inhibitors like anastrozole tend to have higher systolic blood pressure readings than comparable controls, and the underlying biology offers a plausible explanation. But when researchers pool data from large trials, the size of the effect varies considerably, and some analyses fail to reach statistical significance. The story gets further complicated by the fact that most major trials compared anastrozole to tamoxifen rather than to no treatment at all, making it hard to separate a real blood pressure increase from the possibility that tamoxifen was lowering blood pressure on the other side of the comparison.

What the Clinical Data Actually Show

The most direct evidence comes from a pilot study that measured blood pressure and vascular function in breast cancer survivors taking aromatase inhibitors. Women on these drugs had a mean systolic blood pressure of about 129 mmHg, compared to roughly 116 mmHg in matched controls who were not taking them. That gap of around 12 points is clinically meaningful and was statistically significant.¹ A reading of 129 mmHg puts you in the elevated-to-stage-1 hypertension range, whereas 116 is comfortably normal.

The picture gets murkier when you look at larger pooled analyses. A systematic review and meta-analysis that combined five trials comparing aromatase inhibitors to tamoxifen found that the odds of developing hypertension were about 31% higher for women taking aromatase inhibitors. However, that result did not reach statistical significance, meaning the researchers could not rule out that the difference was due to chance. The studies also showed high variability between trials. One individual trial, called TEAM, did report a statistically significant 40% increase in hypertension risk with aromatase inhibitors compared to tamoxifen.²

So the clinical picture is not that anastrozole dramatically spikes blood pressure in everyone who takes it. It is more that blood pressure tends to creep upward, sometimes by a meaningful amount, and the effect is real enough to show up in careful measurements even when larger, noisier trial datasets struggle to confirm it conclusively.

Why Blocking Estrogen Affects Your Blood Vessels

Anastrozole works by shutting down the enzyme aromatase, which your body uses to produce estrogen. In postmenopausal women, aromatase is the primary remaining source of estrogen, so blocking it drops estrogen levels dramatically. That is the whole point for breast cancer treatment, since many breast tumors depend on estrogen to grow. But estrogen does more than fuel cancer cells. It also plays an active role in keeping blood vessels relaxed and flexible.

Estrogen triggers the production of nitric oxide in the cells lining your arteries. Nitric oxide is one of the body’s most important signals for telling blood vessel walls to relax and widen. Research has shown that estrogen rapidly increases the activation of the enzyme responsible for nitric oxide production, and that this directly causes arteries to relax in a dose-dependent fashion.³ When you remove estrogen from the equation by blocking aromatase, that relaxation signal weakens, and blood vessels become stiffer and more constricted. The result is higher resistance to blood flow and, consequently, higher blood pressure.

Animal studies reinforce this mechanism. In female rats treated with an aromatase inhibitor, mean arterial pressure increased compared to untreated controls. The same rats also showed signs of kidney stress, including higher levels of albumin in their urine and markers of tubular injury in their kidneys.⁴ The kidneys play a central role in blood pressure regulation, so damage there could amplify the vascular effects of estrogen loss, creating a two-pronged path toward higher readings.

How Anastrozole Compares to Other Aromatase Inhibitors

Anastrozole is one of three aromatase inhibitors commonly prescribed for hormone-receptor-positive breast cancer in postmenopausal women. The other two are letrozole and exemestane. All three block estrogen production, but they are not interchangeable when it comes to cardiovascular side effects.

In the pilot study measuring vascular function, women taking anastrozole specifically had lower large artery elasticity than those on exemestane or letrozole. The median measure of large artery elasticity for anastrozole users was 11.7, compared to 14.6 for exemestane and 13.9 for letrozole, a difference that was statistically significant.⁵ Stiffer arteries mean the heart has to work harder to push blood through, which typically translates to higher systolic blood pressure.

A comparative review of cardiovascular safety profiles across third-generation aromatase inhibitors concluded that these drugs should not be treated as equivalent in clinical practice.⁶ This matters if you are already dealing with blood pressure concerns. Exemestane, which is a steroidal inhibitor rather than a nonsteroidal one like anastrozole and letrozole, may have a slightly different cardiovascular profile, though the data are not robust enough to make firm ranking claims across all outcomes. The point is that if blood pressure becomes a problem on anastrozole, switching to a different aromatase inhibitor is a conversation worth having with your oncologist rather than simply stopping therapy.

The Tamoxifen Comparison Problem

Most of the large clinical trials that tracked cardiovascular outcomes with anastrozole used tamoxifen as the comparator drug rather than a placebo. This is a meaningful limitation when trying to answer whether anastrozole causes high blood pressure. Tamoxifen is a selective estrogen receptor modulator and may have its own mild protective effects on the cardiovascular system. If tamoxifen lowers blood pressure or improves lipid profiles slightly, then any comparison that shows anastrozole performing “worse” may be overstating the actual risk of anastrozole alone.

Data from the landmark ATAC trial, which followed over 6,000 women, illustrate this ambiguity. At 68 months, the rate of ischemic heart disease was not significantly higher with anastrozole compared to tamoxifen. Rates of angina were slightly elevated in the anastrozole group but did not reach statistical significance. Myocardial infarction rates were essentially identical in both arms, and cardiovascular death rates were similar as well.⁷

However, a separate meta-analysis comparing aromatase inhibitors to tamoxifen across multiple trials found statistically significant increases in the risk of ischemic heart disease, heart failure, and other cardiovascular events with aromatase inhibitors.⁸ This does not necessarily mean anastrozole is dangerous in absolute terms, but it does suggest that the cardiovascular protection offered by tamoxifen can mask a real difference when comparing the two head to head. When researchers have compared aromatase inhibitors to placebo rather than tamoxifen, the differences in hypertension risk tend to be smaller and often not statistically significant, as the pooled analysis described earlier showed.²

The practical takeaway is that if you are switching from tamoxifen to anastrozole, your blood pressure may rise somewhat, but the cause might be losing tamoxifen’s modest cardiovascular benefits as much as gaining a direct harmful effect from anastrozole. And if you are starting anastrozole as your first endocrine therapy with no prior tamoxifen use, the absolute increase in blood pressure risk appears smaller than the head-to-head trial numbers might suggest.

Does Longer Treatment Mean More Risk?

Aromatase inhibitor therapy typically runs for five years, though some women are prescribed extended courses of seven to ten years. A natural question is whether staying on anastrozole for longer pushes blood pressure higher over time. The evidence says no, at least for hypertension specifically. A systematic review and meta-analysis of extended adjuvant therapy found no association between longer duration of aromatase inhibitor use and increased odds of hypertension. About 7.3% of women on longer treatment courses reported hypertension, compared to 7.1% in the control group, a vanishingly small absolute difference that was not statistically significant.⁹

This is somewhat reassuring. It suggests that if your blood pressure is going to respond to anastrozole, it will likely do so relatively early in treatment rather than progressively worsening year after year. Women who tolerate the drug well from a cardiovascular standpoint in the first year or two are unlikely to develop new hypertension as a late surprise. That said, blood pressure naturally tends to rise with age, so anyone on a multi-year course of treatment should have regular monitoring regardless.

Endothelial Function and Arterial Stiffness

Blood pressure readings capture only part of the cardiovascular story. Researchers are increasingly interested in what anastrozole does to the health of the blood vessel lining itself, known as endothelial function. In the pilot study mentioned earlier, women on aromatase inhibitors had dramatically worse endothelial function compared to controls. Their EndoPAT ratio, a measure of how well the arterial lining responds to changes in blood flow, was 0.8 compared to 2.7 in controls. That difference remained significant even after adjusting for systolic blood pressure, meaning it was not simply a downstream consequence of having higher readings.⁵

Poor endothelial function is considered an early warning sign for atherosclerosis and future cardiovascular events. Blood vessels that cannot properly dilate in response to increased demand are more prone to damage over time. This finding matters because it implies that even if a woman’s blood pressure numbers stay within a normal range on anastrozole, the underlying vascular health may still be deteriorating in ways that a standard blood pressure cuff will not catch. Interestingly, a small study in young men who were given an aromatase inhibitor showed no change in systemic arterial compliance, suggesting that the effect may be more pronounced in postmenopausal women whose estrogen levels are already low to begin with.¹⁰

Cholesterol and Metabolic Side Effects

Blood pressure does not exist in isolation. A drug that modestly raises blood pressure while also worsening cholesterol could compound cardiovascular risk in ways that neither effect would alone. The evidence on anastrozole and cholesterol is genuinely conflicting. Some studies show anastrozole has little effect on lipids, while others indicate it worsens cholesterol profiles or increases rates of hypercholesterolemia.¹¹

A large observational study of nearly 8,000 women on aromatase inhibitor therapy (mostly letrozole rather than anastrozole) found that the change in LDL cholesterol was almost identical whether women were on the drug or not. The adjusted difference was essentially zero.¹² This is reassuring, though it is worth noting that the study population was predominantly on letrozole, and lipid effects may differ between individual aromatase inhibitors just as vascular effects do.

For practical purposes, if you are on anastrozole, it makes sense to have your lipid panel checked periodically alongside blood pressure monitoring. The concern is not that cholesterol will skyrocket but rather that small, simultaneous shifts in multiple cardiovascular risk factors can add up, especially in postmenopausal women who already face rising baseline risk.

Exercise as a Countermeasure

One of the more encouraging findings in this area is that structured physical activity can meaningfully counteract the metabolic side effects of aromatase inhibitors. A study of postmenopausal breast cancer patients undergoing aromatase inhibitor therapy tested a combined physical exercise and health education program and found that the intervention significantly reduced hypertension, central obesity, and triglyceride levels in participants.¹³

This matters because many women on anastrozole understandably focus on cancer recurrence prevention and may not prioritize cardiovascular fitness. But the evidence suggests that regular aerobic exercise can directly offset some of the blood pressure and metabolic effects of estrogen deprivation. You do not need an elaborate regimen; consistent moderate-intensity activity, the kind where you can still hold a conversation but are slightly out of breath, is what the research supports. Walking, cycling, swimming, and similar activities all fit the bill.

Beyond exercise, standard blood-pressure-friendly habits apply with particular force when you are on anastrozole: keeping sodium intake reasonable, maintaining a healthy weight, limiting alcohol, and managing stress. These are the same recommendations any doctor would make for anyone with borderline blood pressure, but they carry extra weight when your medication is potentially nudging your numbers upward.

Why Adherence Still Matters

Cardiovascular side effects, including rising blood pressure, are one of several reasons women stop taking aromatase inhibitors before completing their prescribed course. Joint pain and musculoskeletal symptoms are the most common complaints, but concerns about heart health contribute to the problem. Adherence to these drugs matters because the cancer-prevention benefit depends on sustained use over years. Dropping off therapy early because of side effects that could have been managed with monitoring and intervention is a real clinical problem.¹⁴

If your blood pressure rises on anastrozole, the answer in most cases is not to stop the drug but to treat the blood pressure. Standard antihypertensive medications work normally in this context. Your oncologist and primary care provider can coordinate to add or adjust blood pressure treatment while keeping you on the cancer therapy that is protecting you from recurrence. The key is catching the change early, which means having your blood pressure checked at regular intervals throughout treatment rather than assuming a normal baseline reading will persist for five years.

Some women find it helpful to invest in a home blood pressure monitor. A few readings per week, taken at roughly the same time of day, provide a far more accurate picture of what your blood pressure is actually doing than the occasional clinic visit, where white-coat effects and timing can distort the numbers. If you see a consistent upward trend, bring those readings to your next appointment rather than waiting for a single high reading at the clinic to trigger a response.

1
PubMed Central. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study
2
PubMed Central. Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis – Section: 3.3 Arterial Hypertension
3
The Journal of Pharmacology and Experimental Therapeutics. Cardiovascular Role of Neuronal Nitric-Oxide Synthase in Estrogen-Induced Relaxation in Rat Resistance Arteries
4
PubMed Central. Aromatase inhibition increases blood pressure and markers of renal injury in female rats
5
PubMed Central. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study – Section: Results
6
PubMed. Cardiovascular safety profiles of aromatase inhibitors: a comparative review
7
International Heart and Vascular Disease Journal. The adverse cardiovascular effects of aromatase inhibitors and its management in patients with breast cancer
8
Karger. The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis
9
Oxford Academic. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
10
PubMed. Endogenous estrogens influence endothelial function in young men
11
PubMed Central. The effects of aromatase inhibitors on lipids and thrombosis
12
PubMed Central. Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer
13
PubMed Central. Impact of a Physical Exercise and Health Education Program on Metabolic Syndrome and Quality of Life in Postmenopausal Breast Cancer Women Undergoing Adjuvant Treatment with Aromatase Inhibitors – Section: Results
14
PubMed Central. Precautions for Patients Taking Aromatase Inhibitors